Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132773 | 0.89 | ALDH1A1 (0.78) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL16490235 | 0.83 | ALDH1A1 (0.64) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL28453082 | 0.83 | KMT2A (0.45) | ALDH1A1KMT2AMEN1POLBMAPK1 | |
| SCHEMBL10604973 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL126492 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL11315920 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| SCHEMBL4198688 | 0.83 | ALDH1A1 (0.69) | ALDH1A1CYP3A4KMT2AMEN1CA2 | |
| P-Xylene SCHEMBL9685877 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP3A4CA2MAPT | |
| SCHEMBL873414 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP3A4CA2MAPT | |
| SCHEMBL7184720 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP3A4KMT2AMEN1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | PURDUE RESEARCH FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9662402-B2 | Drug delivery conjugates containing unnatural amino acids and methods for using | ENDOCYTE, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150258203-A1 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING | ENDOCYTE, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ALDH1A1 642/4885CYP3A4 4580/4885KMT2A 961/4885 |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | ALDH1A1 1100/4885CYP3A4 3105/4885KMT2A 1101/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ALDH1A1 642/4885CYP3A4 4580/4885KMT2A 961/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ALDH1A1 642/4885CYP3A4 4580/4885KMT2A 961/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ALDH1A1 642/4885CYP3A4 4580/4885KMT2A 961/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ALDH1A1 642/4885CYP3A4 4580/4885KMT2A 961/4885 |
| US-20150258203-A1 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING | SLC1A5, SLC7A1, DNPEP | ALDH1A1 965/4885CYP3A4 4543/4885KMT2A 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.